The U.S. FDA on Tuesday requested Novo Nordisk (NVO) and Eli Lilly (LLY) to implement labeling changes for their blockbuster weight loss drugs to reflect that there is no increased risk of suicidal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results